EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review

Nicola Ferri iD, Massimiliano Ruscica iD, Sergio Fazio, Alberto Corsini

Journal of Clinical Medicine · 07.02.2024 · 13 (4) · 943

DOI: 10.3390/jcm13040943 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.02.2024. Verfasst von Nicola Ferri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Governo Italiano, Italian Ministry of University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo identified an active compound (compactin) that inhibited cholesterol biosynthesis from the culture broth of blue–green mold (Penicillium citrinum Pen-51). Since 1987, statins have represented the milestone for the treatment of atherosclerotic cardiovascular disease. A new therapy for the treatment of hypercholesterolemia since the discovery of statins is ezetimibe, the first and only agent inhibiting intestinal cholesterol absorption. Ezetimibe was approved by the FDA in October 2002. A year later, the association between gain-of-function PCSK9 genetic mutations and hypercholesterolemia was reported, and this discovery opened a new era in lipid-lowering therapies. Monoclonal antibodies and small-interfering RNA approaches to reduce PCSK9 were developed and approved for clinical use in 2015 and 2022, respectively. Finally, the newly approved bempedoic acid, an oral adenosine triphosphate citrate lyase inhibitor that lowers LDL-C, is able to reduce major adverse cardiovascular events in both primary and secondary prevention. In the present narrative review, we summarize the pharmacological properties and the clinical efficacy of all these agents currently used for a tailored therapy of hypercholesterolemia in patients with atherosclerotic cardiovascular disease.

Schlagwörter

Stichwörter der Autor:innen

LDL-cholesterolPCSK9bempedoic acidezetimibeinclisiranstatins

Autor:innen und Institutionen

  • Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy.
  • Veneto Institute of Molecular Medicine (VIMM), 35129 Padua, Italy.
  • Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, 20133 Milan, Italy.
  • Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
  • Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.

ORCID-Profile: Nicola Ferri, Massimiliano Ruscica

Förderung

  • Governo Italiano
  • Italian Ministry of University and Research

Zitieren

APA

Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024). Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. Journal of Clinical Medicine, 13(4), 943. https://doi.org/10.3390/jcm13040943

Vancouver

Ferri N, Ruscica M, Fazio S, Corsini A. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. Journal of Clinical Medicine. 2024;13(4):943. doi:10.3390/jcm13040943

BibTeX
@article{Ferri2024,
  author = {Ferri, Nicola and Ruscica, Massimiliano and Fazio, Sergio and Corsini, Alberto},
  title = {Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {943},
  doi = {10.3390/jcm13040943}
}
Kostenlos starten →